Current perspectives on ranibizumab

Vaidehi S Dedania,1 Sophie J Bakri21Department of Ophthalmology, Albany Medical Center, Lions Eye Institute, Albany, NY, USA; 2Department of Ophthalmology, Mayo Clinic, Rochester, MN, USABackground: This review summarizes the Phase III studies addressing intravitreal ranibizumab treatment in patien...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dedania VS, Bakri SJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/095644ceffa5427ba9b3b4bd05e586bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:095644ceffa5427ba9b3b4bd05e586bc
record_format	dspace
spelling	oai:doaj.org-article:095644ceffa5427ba9b3b4bd05e586bc2021-12-02T00:53:41ZCurrent perspectives on ranibizumab1177-5483https://doaj.org/article/095644ceffa5427ba9b3b4bd05e586bc2015-03-01T00:00:00Zhttp://www.dovepress.com/current-perspectives-on-ranibizumab-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Vaidehi S Dedania,1 Sophie J Bakri21Department of Ophthalmology, Albany Medical Center, Lions Eye Institute, Albany, NY, USA; 2Department of Ophthalmology, Mayo Clinic, Rochester, MN, USABackground: This review summarizes the Phase III studies addressing intravitreal ranibizumab treatment in patients with neovascular age-related macular degeneration (AMD), macular edema (ME) from retinal vein occlusion (RVO), and diabetic ME (DME).Results: The data from 12 major Phase III studies: six studies in patients with neovascular AMD, two studies in patients with ME from RVO, and four studies in patients with DME demonstrate significant improvement in vision in patients undergoing treatment with intravitreal ranibizumab over patients receiving no treatment or receiving only grid laser. These effects are achieved with low incidences of ocular and nonocular adverse events.Conclusion: Intravitreal ranibizumab is a highly effective and safe therapy for improving vision and reducing vision loss in patients with neovascular AMD, ME from RVO, and DME. Patients generally require long-term treatment although some data show that frequency of treatment necessary to maintain visual outcomes decreases over time.Keywords: age-related macular degeneration, branch retinal vein occlusion, central retinal vein occlusion, diabetic macular edema, intravitreal, macular edemaDedania VSBakri SJDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 533-542 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Dedania VS Bakri SJ Current perspectives on ranibizumab
description	Vaidehi S Dedania,1 Sophie J Bakri21Department of Ophthalmology, Albany Medical Center, Lions Eye Institute, Albany, NY, USA; 2Department of Ophthalmology, Mayo Clinic, Rochester, MN, USABackground: This review summarizes the Phase III studies addressing intravitreal ranibizumab treatment in patients with neovascular age-related macular degeneration (AMD), macular edema (ME) from retinal vein occlusion (RVO), and diabetic ME (DME).Results: The data from 12 major Phase III studies: six studies in patients with neovascular AMD, two studies in patients with ME from RVO, and four studies in patients with DME demonstrate significant improvement in vision in patients undergoing treatment with intravitreal ranibizumab over patients receiving no treatment or receiving only grid laser. These effects are achieved with low incidences of ocular and nonocular adverse events.Conclusion: Intravitreal ranibizumab is a highly effective and safe therapy for improving vision and reducing vision loss in patients with neovascular AMD, ME from RVO, and DME. Patients generally require long-term treatment although some data show that frequency of treatment necessary to maintain visual outcomes decreases over time.Keywords: age-related macular degeneration, branch retinal vein occlusion, central retinal vein occlusion, diabetic macular edema, intravitreal, macular edema
format	article
author	Dedania VS Bakri SJ
author_facet	Dedania VS Bakri SJ
author_sort	Dedania VS
title	Current perspectives on ranibizumab
title_short	Current perspectives on ranibizumab
title_full	Current perspectives on ranibizumab
title_fullStr	Current perspectives on ranibizumab
title_full_unstemmed	Current perspectives on ranibizumab
title_sort	current perspectives on ranibizumab
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/095644ceffa5427ba9b3b4bd05e586bc
work_keys_str_mv	AT dedaniavs currentperspectivesonranibizumab AT bakrisj currentperspectivesonranibizumab
_version_	1718403417535152128

Current perspectives on ranibizumab

Ejemplares similares